Keynote Speakers
Gyongyi Szabo Professor & Vice Chair for Research, Department of Medicine, University of Massachusetts Medical School |
Phil Stephens Chief Scientific Officer, Foundation Medicine |
Frank Slack Director, Institute for RNA Medicine, Beth Israel Deaconess Medical Center Cancer Center/Harvard Medical School |
John Palma Chief Medical Officer, Roche Sequencing Solutions |
Shannon Stott Assistant Professor, Massachusetts General Hospital & Harvard Medical School |
Peter Quesenberry Professor of Medicine, The Warren Alpert Medical School of Brown University |
|
Clark Chen Co-Director, University of California-San Diego |
Shana Kelley Professor, University of Toronto |
Stefan Momma Group Leader, University Hospital Frankfurt |
Xandra Breakefield Professor, Mass General Hospital (MGH)/Harvard Medical School |
Chwee Teck Lim NUS Society Chair Professor, Department of Biomedical Engineering, Institute for Health Innovation & Technology (iHealthtech), Mechanobiology Institute, National University of Singapore |
Bob Carter Professor and Chief of Neurosurgery, Massachusetts General Hospital, Harvard Medical School |
Steve Soper Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine, The University of Kansas |
Saumya Das Assistant Professor in Medicine, Beth Israel Deaconess Medical Center and Mass General Hospital |
Joshua Levin Senior Group Leader, Research Scientist, Stanley Center for Psychiatric Research, Klarman Cell Observatory, The Broad Institute of MIT and Harvard |
Overview
The 3rd. Annual SELECTBIO Circulating Biomarkers World Congress 2016 brings together academic researchers as well as industry participants to present and discuss the most up-to-date research and commercial activities in the translation of various circulating biomarker classes towards the clinic.
This Congress discusses Nucleic Acid-based Biomarkers, Protein-based Biomarkers, Extracellular Vesicle (EV)-based Biomarkers (contained within exosomes and microvesicles), and Circulating Tumor Cell (CTC)-based Biomarkers.
|
|
One of the conference tracks focuses on Liquid Biopsies as the fields of Circulating Biomarkers and Liquid Biopsy development are converging and the various classes of Circulating Biomarkers may be developed into liquid biopsies for cancer and several other disease classes. A co-located exhibit hall features companies developing technologies and products for the complete workflow from sample isolation, preparation, through data analysis. Conference delegates receive access to all three co-located conference tracks, can mix-and-match presentations from all three tracks thereby maximizing the conference experience, and can network with delegates from the various co-located tracks and exhibition.
Agenda and Information for:
|
|
|
Corporate Sponsors
|
Media Sponsors
|
|
Networking
|
|
|
|
|
|